CTOs on the Move

Carlmont Gardens Nursing

www.carlmontgardens.com

 
When it comes to selecting a nursing home, you want as much information as possible. You’ll want to be sure that we offer skilled care. You’ll need to assure yourself that you’re dealing with a facility that’s thoroughly professional while also being genuinely caring and considerate at all times. And you’ll insist upon a commitment to service that goes well beyond the everyday.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Metabolon, Inc.

Metabolon, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Durham, NC. To find more information about Metabolon, Inc., please visit www.metabolon.com

Georgia Pediatric Pulmonology Associates

Georgia Pediatric Pulmonology Associates is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Medical

Care Medical is a Maumelle, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hospice El Paso

Hospice El Paso, Inc. is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.